Targeting EGFR^L858R/T790M and EGFR^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal...

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• First- and second-generation EGFR inhibitors improved survival in NSCLC patients with EGFR mutations.
• Acquired resistance to these drugs often involves secondary EGFR T790M mutations.
• Tertiary EGFR C797S mutations cause resistance to third-generation inhibitors.

Purpose of the Study:

• To review mechanisms of acquired resistance to EGFR inhibitors in NSCLC.
• To summarize medicinal chemistry advances in third- and fourth-generation EGFR inhibitors.
• To focus on novel inhibitors targeting the EGFR C797S resistance mutation.

Main Methods:

• Literature review of acquired resistance mechanisms.
• Analysis of medicinal chemistry strategies for EGFR inhibitor development.
• Focus on third- and fourth-generation inhibitors, including allosteric and reversible agents.

Main Results:

• EGFR T790M and EGFR C797S mutations are key resistance mechanisms.
• Third-generation inhibitors like AZD9291 target EGFR T790M.
• Development of fourth-generation inhibitors is ongoing to combat tertiary mutations.

Conclusions:

• Overcoming acquired resistance is crucial for improving NSCLC outcomes.
• Novel EGFR inhibitors, particularly those targeting EGFR C797S, are highly desirable.
• Allosteric and reversible inhibitors show promise against tertiary resistance mutations.